Ignite Creation Date:
2024-05-05 @ 11:10 PM
Last Modification Date:
2024-10-26 @ 10:30 AM
Study NCT ID:
NCT01277653
Status:
UNKNOWN
Last Update Posted:
2011-01-17
First Post:
2011-01-14
Brief Title:
Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma
Sponsor:
Yonsei University
Organization:
Yonsei University
Study Overview
Official Title:
Prospective Randomized Study of PIVKA-II and AFP Measurement Every 3 Months Compared to AFP Every 6 Months in Surveillance Program for Early Detection of Hepatocellular Carcinoma
Status:
UNKNOWN
Status Verified Date:
2009-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is no prospective study on the test intervals of alpha-fetoprotein AFP or on the role of prothrombin induced vitamin K absence or antagonist-II PIVKA-II in surveillance program for early detection of hepatocellular carcinomaHCC The goal of this study is to compare if the testing of AFP PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used
Detailed Description:
There is no prospective study on the test intervals of alpha-fetoprotein AFP or on the role of prothrombin induced vitamin K absence or antagonist-II PIVKA-II in surveillance program for early detection of hepatocellular carcinomaHCC The goal of this study is to compare if the testing of AFP PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None